Boccia, MD, FACP, founder of The Center for Cancer and Blood Disorders, clinical associate professor at MedStar Georgetown ...
A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...
The FDA has granted fast track designation to VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted PRO-XTEN® ...
The safety profile is one of the biggest advantages of CAR NK cells, and that is exciting for the field because NK cells do ...
Just weeks after the FDA approved an all-oral regimen for newly diagnosed acute myeloid leukemia (AML), a panel of leukemia ...
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as ...
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility ...
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with ...
The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with ...
Chirag Jain, MBBS, discussed onco-anxiology, a proposed framework for identifying and managing anxiety at each stage of the ...
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases. The University of Pittsburgh Medical Center (UPMC) faculty have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results